February 15, 2021 – ADM Diagnostics (ADMdx) has published its findings from a study of the drug rasagiline in patients with Alzheimer’s disease. ADMdx performed the image analysis for this study, which was led by Dr. Jeffrey Cummings of the Lou Ruvo Center for Brain Health, Cleveland Clinic. ADMdx applied methods of measuring changes in brain activity measured using PET imaging of glucose metabolism.  The analyses revealed a treatment effect consistent with the monoamine inhibition properties of rasagiline. ADMdx also applied machine learning classification software to confirm the likelihood of Alzheimer’s disease in the study participants. Results matched the tau burden that was observed in these patients, measured using tau PET.

November 3, 2020 – ADM Diagnostics has received a patent on a novel method to detect and adjust for variability in PET scans.  PET scans of the brain can measure abnormal proteins such as amyloid or tau, and other characteristics.  In developing treatments for disease, it is very important to be able to measure small changes over time. This is often difficult due to technical “noise” in the scan.  ADMdx has developed a method to detect and correct for variability in the PET signal that allows for improved detection of the effects of disease and treatment.

September 30, 2020 – ADM Diagnostics has received a patent on a method that obtains information from a brain scan that would typically take much longer to measure. The first few minutes of a positron emission tomography (PET) scan contain information regarding brain blood flow and function.  Information regarding the amount of amyloid burden or other entities is not obtained until many minutes later.  To obtain both types of information requires scanning the patient for a long time or in two parts.  ADMdx’s method is able to obtain both types of information using the first 20 or less minutes. This has application in Alzheimer’s disease and in other brain disorders.

ADMdx will present findings regarding the presence of tau, an abnormal protein, in Alzheimer’s patients, at the Tau2020 conference to be held in Washington DC on February 12.  This work describes the diverse burden of tau in individuals with Alzheimer’s disease, and relationships to brain atrophy, glucose metabolism, age, gender, and clinical status.

ADMdx will present findings regarding relationships between tau, glucose metabolism, brain atrophy, and patient characteristics at the ADPD conference in April 2020. These analyses used a unique data set acquired through the Phase II study of the drug rasagiline in Alzheimer’s disease patients in collaboration with Dr. Jeffrey Cummings of the Cleveland Clinic. The data provides new insights regarding these biomarkers in Alzheimer’s disease.

Dawn Matthews, CEO, presented results of ADMdx’s analysis of image data for a Phase II clinical trial of the drug rasagiline in Alzheimer’s disease patients at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Diego.  The trial was led by Dr. Jeffrey Cummings of the Lou Ruvo Center for Brain Health at the Cleveland Clinic, in collaboration with the Alzheimer’s Disease Cooperative Study (ADCS) and the Alzheimer’s Drug Discovery Foundation (ADDF). ADMdx’s analysis of FDG PET data showed that rasagiline favorably affected glucose metabolism in frontostriatal regions of the brain, meeting the study’s primary endpoint. Clinical results also showed improvements in Quality of Life and in cognition associated with executive function.

Dawn Matthews, ADMdx CEO, was one of three speakers in an invited panel presentation at the Alzheimer’s Drug Discovery Foundation (ADDF) luncheon on November 1, 2019 in New York.  The panelists described the results of their studies, each focused on repurposing currently approved medications for use in Alzheimer’s disease. Ms. Matthews related the successful outcome of the Phase II clinical trial of rasagiline, led by Dr. Jeffrey Cummings of the Cleveland Clinic.  Image analyses were performed by ADMdx.

New results from ADMdx’s collaborative work on the Down syndrome Biomarker Initiative (DSBI) study led by Dr. Michael Rafii of the University of Southern California has been published.  These results show the correlation between imaging biomarkers and increases in NeuroFilament Light (NF-L), a blood-based marker of neurodegeneration. The manuscript is published in the journal Alzheimer’s & Dementia, titled “Plasma Neurofilament Light and Alzheimer’s Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI)”.

ADMdx will present the results of machine learning classification of different Alzheimer’s disease variants and non Alzheimer’s dementias using three different modalities:  structural MRI, glucose metabolism using FDG PET, and early timeframes of amyloid PET scans.  This work was conducted in collaboration with researchers from the Memory and Aging Center of the University of California, San Francisco. The research will be presented orally on July 25th at the Alzheimer’s Association International Conference in Chicago.

ADMdx will present the results of machine learning classification of brain images from impaired and unimpaired boxers, and their differentiation from Alzheimer’s disease images, at the Alzheimer’s Association International Conference on July 22, 2018. This work was conducted in collaboration with Dr. Charles Bernick and other researchers at the Cleveland Clinic, using structural MRI scans from fighters acquired through the Professional Fighters Brain Health Study.